Malta - English - Medicines Authority

cherubino limited delf building, sliema road, gzira, gzr 1637, malta - gelatin, magnesium chloride, hexahydrate, sodium chloride, sodium lactate - solution for infusion - gelatin 3 g magnesium chloride hexahydrate 0.0305 g sodium chloride 0.5382 g sodium lactate 0.336 g - blood substitutes and perfusion solutions

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi limited - modified liquid gelatine, sodium chloride, magnesium chloride hexahydrate, potassium chloride, sodium lactate solution - solution for infusion - 3 grams - blood substitutes and plasma protein fractions

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi limited - modified liquid gelatine, sodium chloride, magnesium chloride hexahydrate, potassium chloride, sodium lactate solution - solution for infusion - 3 grams - blood substitutes and plasma protein fractions

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - hydroxyethyl starch 130/0.4, quantity: 60 g/l; sodium chloride, quantity: 6.02 g/l; potassium chloride, quantity: 0.3 g/l; magnesium chloride hexahydrate, quantity: 0.3 g/l; sodium acetate trihydrate, quantity: 4.63 g/l - injection, intravenous infusion - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - treatment of hypovolaemia due to acute blood loss when crystalloids alone are not considered sufficient. the use of volulyte is not a substitute for the appropriate use of packed red blood cells or fresh frozen plasma.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - potassium chloride, quantity: 0.3 g/l; sodium chloride, quantity: 6.02 g/l; hydroxyethyl starch 130/0.4, quantity: 60 g/l; magnesium chloride hexahydrate, quantity: 0.3 g/l; sodium acetate trihydrate, quantity: 4.63 g/l - injection, intravenous infusion - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - treatment of hypovolaemia due to acute blood loss when crystalloids alone are not considered sufficient. the use of volulyte is not a substitute for the appropriate use of packed red blood cells or fresh frozen plasma.

New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - hydroxyethyl starch 130/0.4 60 g/l; magnesium chloride hexahydrate 0.3 g/l;  ; potassium chloride 0.3 g/l; sodium acetate trihydrate 4.63 g/l;  ; sodium chloride 6.02 g/l;  ;  ;   - solution for infusion - 6 % - active: hydroxyethyl starch 130/0.4 60 g/l magnesium chloride hexahydrate 0.3 g/l   potassium chloride 0.3 g/l sodium acetate trihydrate 4.63 g/l   sodium chloride 6.02 g/l       excipient: hydrochloric acid sodium hydroxide water for injection - treatment of hypovolaemia due to acute blood loss when chrystlloids alone are not considered sufficient. the use of volulyte is not a substitute for the appropriate use of packed red blood cells or fresh frozen plasma.

Malta - English - Medicines Authority

b braun melsungen ag carl-braun-strasse 1, d34212 melsungen, germany - calcium chloride, dihydrate, gelatin, potassium chloride, magnesium chloride, hexahydrate, sodium acetate, trihydrate, sodium chloride - solution for infusion - calcium chloride dihydrate 0.15 g/l gelatin 40 g/l potassium chloride 0.3 g/l magnesium chloride hexahydrate 0.2 g/l sodium acetate trihydrate 3.27 g/l sodium chloride 5.55 g/l - blood substitutes and perfusion solutions

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - phentermine hydrochloride, quantity: 37.332 mg - capsule, modified release - excipient ingredients: gelatin; liquid paraffin; magnesium stearate; titanium dioxide; sodium polystyrene sulfonate; iron oxide red; lactose monohydrate; iron oxide black; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; potassium hydroxide - phentermine is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater. the treatment with phentermine can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - modified liquid gelatine; sodium chloride; magnesium chloride hexahydrate; potassium chloride; sodium lactate solution - solution for infusion - 3 gram(s) - blood substitutes and plasma protein fractions

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - modified liquid gelatine; sodium chloride; magnesium chloride hexahydrate; potassium chloride; sodium (s)-lactate solution - solution for infusion - 3 gram(s) - blood substitutes and plasma protein fractions